Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
- Patient Education: Reading
- Dec 1, 2022
- 1 min read
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
MARCH 07, 2022 - TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.